Table 2. Factors associated with HBV DNA suppression after 48 weeks of treatment stratified by baseline HBV DNA.
| Baseline HBV DNA <20,000 IU/ml | |||||
|---|---|---|---|---|---|
| HBV DNA Suppression rate at week 48 [n/N (%)] | Crude RR (95%CI) | P | Adjusted RR(95%CI) | P | |
| cART | |||||
| 3TC-based | 30/31 (96.8) | Reference | Reference | ||
| TDF+3TC-based | 50/51 (98.0) | 1.01 (0.94-1.09) | 0.74 | 1.01 (0.93-1.11) | 0.78 |
| CD4 cell count | |||||
| ≤200 cells/μl | 35/37 (94.6) | Reference | Reference | ||
| >200 cells/μl | 45/45 (100.0) | 1.06 (0.98-1.14) | 0.16 | 1.03 ( 0.98-1.09) | 0.22 |
| Baseline HIV RNA (per 1 log copy/ml increase) | Not applicable | 0.97 (0.91-1.03) | 0.28 | ||
| Baseline HBV DNA (per 1 logIU/ml increase) | Not applicable | 1.00 (0.97-1.03) | 0.83 | 1.00 (0.97-1.03) | 0.99 |
| CD4 count at week 48 (cells/μL) | |||||
| ≤350 | 35/37 (94.6) | Reference | |||
| >350 | 45/45 (100.0) | 1.06 (0.98-1.14) | 0.16 | ||
| Baseline HBV DNA ≥20,000 IU/ml | |||||
| HBV DNA Suppression rate at week 48 [n/N (%)] | Crude RR (95%CI) | P | Adjusted RR(95%CI) | P | |
| cART | |||||
| 3TC-based | 10/29 (34.5) | Reference | Reference | ||
| TDF+3TC-based | 29/40 (72.5) | 2.10 (1.22-3.61) | 0.007 | 1.98 (1.18-3.34) | 0.010 |
| CD4 cell count | |||||
| ≤200 cells/μl | 23/39 (59.0) | Reference | |||
| >200 cells/μl | 16/30 (53.3) | 0.90 (0.59-1.39) | 0.65 | 0.66 (0.46-0.96) | 0.028 |
| Baseline HIV RNA (per 1 log copy/ml) increase | Not applicable | 1.12 (0.85-1.48) | 0.43 | ||
| Baseline HBV DNA (per 1 log IU/ml increase) | Not applicable | 0.74 (0.65-0.85) | <0.001 | 0.74 (0.63-0.87) | <0.001 |
| CD4 count at week 48 (cells/μL) | |||||
| ≤350 | 20/37 (54.1) | Reference | |||
| >350 | 19/32 (59.4) | 1.10 (0.72-1.66) | 0.66 | ||
RR, relative risk; cART, combination antiretroviral therapy; 3TC, lamivudine; TDF, tenofovir.
a
Since baseline CD4 cell count were not balanced in two treatment groups, we also adjusted for baseline CD4 cell count in multivariate models.
b
Sex, age and routes of transmission were also adjusted for in multivariate analyses. Of note, they were not significantly associated with HBV DNA suppression in univariate analysis. cART regimens (3TC-based or TDF+3TC-based), baseline HBV DNA and baseline CD4 cell count were forced into the multivariate models; other factors with P values<0.15 in univariate models were also included in the multivariate models.